Market Overview

UPDATE: JMP Securities Raises PT on BioCryst Pharmaceuticals on Potential Game Changer

Related BCRX
Ebola Vaccine Contenders
Sarepta Therapeutics Shares Up On Ebola Drug Safety Study
Making Money With Charles Payne: 10/24/14 (Fox Business)

In a report published Wednesday, JMP Securities analyst Liisa A. Bayko reiterated a Market Outperform rating on BioCryst Pharmaceuticals (NASDAQ: BCRX), and raised the price target from $5.00 to $8.00.

In the report, JMP Securities noted, “Investors see BioCryst's oral kallikrein program as a potential game changer in HAE; we reiterate our Market Outperform rating and increase our price target to $8 from $5. Last week, BioCryst's CEO Jon Stonehouse received a warm welcome from investors for his oral kallikrein program for the prevention of hereditary angioedema attacks (HAE). The company is busy preparing to initiate a Phase 2a proof of concept (POC) study - the first in patients - to determine if BCX4161 can reduce the frequency of attacks in patients with HAE. Amongst a healthy degree of competition in the HAE prophylaxis market, we believe even modest efficacy could carve out a meaningful market opportunity for BioCryst given the number of patients who may consider initiating prophylaxis if there were an oral option. Additionally, a second drug candidate is targeting better bioavailability, which could deliver better efficacy in fewer doses..”

BioCryst Pharmaceuticals closed on Tuesday at $6.44.

Latest Ratings for BCRX

Aug 2014JP MorganInitiates Coverage onOverweight
Jun 2014Wells FargoUpgradesMarket PerformOutperform
Apr 2014Brinson PatrickInitiates Coverage onMarket Outperform

View More Analyst Ratings for BCRX
View the Latest Analyst Ratings

Posted-In: JMP Securities Liisa A. BaykoAnalyst Color Price Target Analyst Ratings


Related Articles (BCRX)

Around the Web, We're Loving...

Get Benzinga's Newsletters